First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors

Prevalence of KRAS p.G12C mutation in patients with metastatic non-small cell lung cancer in Argentina

Site of metastasis and its impact on clinical outcomes in 8 cancer cohorts

LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation

For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care.

Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study

Molecular Tumor Board: 69-year-old male with metastatic urothelial carcinoma with FGFR3 mutation

Labcorp Finalizes Strategic Relationship with Jefferson Health

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health (Jefferson), the largest

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ --  Labcorp  (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 8, 2023 , to stockholders of record